2025
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients
Monagle P, Azzam M, Bercovitz R, Betensky M, Bhat R, Biss T, Branchford B, Brandão L, Chan A, Faustino E, Jaffray J, Jones S, Kawtharany H, Kerlin B, Kucine N, Kumar R, Male C, Pelland-Marcotte M, Raffini L, Raulji C, Sartain S, Takemoto C, Tarango C, van Ommen C, Velez M, Vesely S, Wiernikowski J, Williams S, Wilson H, Woods G, Zia A, Mustafa R. American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients. Blood Advances 2025, 9: 2587-2636. PMID: 40423983, DOI: 10.1182/bloodadvances.2024015328.Peer-Reviewed Original ResearchConceptsPediatric venous thromboembolismGRADE Evidence-to-Decision frameworksEvidence-to-decision frameworkMultidisciplinary guideline panelHealth care professionalsGuideline development processAmerican Society of HematologyUniversity of Kansas Health SystemVenous thromboembolismEvidence-based guidelinesCare professionalsPatient representativesHealth systemPediatric patientsGuideline panelTreatment of pediatric venous thromboembolismManagement of pediatric patientsPediatric guidelinesTreatment of venous thromboembolismTreatment trialsInternational Society on ThrombosisAmerican SocietyGuidelinesImplementation guidancePotential bias
2024
Pharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease
Jaoudeh R, Hartmann P, Olson O, Gupta O, Kumar S, Ibrahim S, Fawaz R, Aqul A, Hassan S. Pharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease. Journal Of Pediatric Gastroenterology And Nutrition 2024, 80: 14-24. PMID: 39526564, DOI: 10.1002/jpn3.12402.Peer-Reviewed Original ResearchGLP-1RABody mass indexLiver diseasePediatric patientsPediatric obesityEfficacy of GLP-1RADisease progressionGlucagon-like peptide-1 receptor agonistsSteatotic liver diseaseManagement of pediatric patientsPeptide-1 receptor agonistsClinical management of pediatric patientsAdverse liver outcomesInduce weight lossLong-term efficacyHepatic manifestation of obesityLiver enzyme levelsAlternative therapeutic strategiesHalting disease progressionManifestation of obesityNonalcoholic fatty liver diseaseChildhood obesity ratesFatty liver diseaseReceptor agonistsLiver transplantation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply